Avantor (AVTR) Competitors

$7.98 -0.33 (-3.91%)

Closing price 05/11/2026 03:59 PM Eastern

Extended Trading

$8.10 +0.12 (+1.45%)

As of 05/11/2026 07:55 PM Eastern

AVTR vs. TECH, A, DHR, RVTY, and TMO

Should you be buying Avantor stock or one of its competitors? The main competitors of Avantor include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Revvity (RVTY), and Thermo Fisher Scientific (TMO). These companies are all part of the "medical" sector.

How does Avantor compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Avantor (NYSE:AVTR) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Bio-Techne has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Avantor has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Bio-Techne has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	6.09	$73.40M	$0.69	68.72
Avantor	$6.55B	0.83	-$530.20M	-$0.81	N/A

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 95.1% of Avantor shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 0.3% of Avantor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bio-Techne had 21 more articles in the media than Avantor. MarketBeat recorded 30 mentions for Bio-Techne and 9 mentions for Avantor. Avantor's average media sentiment score of 1.03 beat Bio-Techne's score of -0.09 indicating that Avantor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	4 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Avantor	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has a net margin of 9.05% compared to Avantor's net margin of -8.42%. Bio-Techne's return on equity of 13.57% beat Avantor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Avantor	-8.42%	9.95%	4.78%

Bio-Techne presently has a consensus price target of $66.77, indicating a potential upside of 40.80%. Avantor has a consensus price target of $11.39, indicating a potential upside of 42.68%. Given Avantor's higher possible upside, analysts plainly believe Avantor is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79
Avantor	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07

Summary

Bio-Techne beats Avantor on 14 of the 17 factors compared between the two stocks.

How does Avantor compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Avantor (NYSE:AVTR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Agilent Technologies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Avantor has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	4.54	$1.30B	$4.53	24.66
Avantor	$6.55B	0.83	-$530.20M	-$0.81	N/A

95.1% of Avantor shares are owned by institutional investors. 0.3% of Avantor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Agilent Technologies had 1 more articles in the media than Avantor. MarketBeat recorded 10 mentions for Agilent Technologies and 9 mentions for Avantor. Avantor's average media sentiment score of 1.03 beat Agilent Technologies' score of 0.97 indicating that Avantor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Avantor	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a net margin of 18.26% compared to Avantor's net margin of -8.42%. Agilent Technologies' return on equity of 24.49% beat Avantor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	18.26%	24.49%	12.83%
Avantor	-8.42%	9.95%	4.78%

Agilent Technologies presently has a consensus price target of $163.71, indicating a potential upside of 46.53%. Avantor has a consensus price target of $11.39, indicating a potential upside of 42.68%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Avantor	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07

Summary

Agilent Technologies beats Avantor on 14 of the 17 factors compared between the two stocks.

How does Avantor compare to Danaher?

Danaher (NYSE:DHR) and Avantor (NYSE:AVTR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Danaher has a net margin of 14.89% compared to Avantor's net margin of -8.42%. Danaher's return on equity of 10.91% beat Avantor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	14.89%	10.91%	6.94%
Avantor	-8.42%	9.95%	4.78%

79.1% of Danaher shares are owned by institutional investors. Comparatively, 95.1% of Avantor shares are owned by institutional investors. 10.8% of Danaher shares are owned by insiders. Comparatively, 0.3% of Avantor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Danaher has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Avantor has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Danaher presently has a consensus price target of $240.70, indicating a potential upside of 44.60%. Avantor has a consensus price target of $11.39, indicating a potential upside of 42.68%. Given Danaher's stronger consensus rating and higher possible upside, analysts plainly believe Danaher is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.86
Avantor	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07

Danaher has higher revenue and earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.57B	4.80	$3.61B	$5.17	32.20
Avantor	$6.55B	0.83	-$530.20M	-$0.81	N/A

In the previous week, Danaher had 18 more articles in the media than Avantor. MarketBeat recorded 27 mentions for Danaher and 9 mentions for Avantor. Danaher's average media sentiment score of 1.26 beat Avantor's score of 1.03 indicating that Danaher is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	21 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Avantor	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Danaher beats Avantor on 14 of the 16 factors compared between the two stocks.

How does Avantor compare to Revvity?

Avantor (NYSE:AVTR) and Revvity (NYSE:RVTY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Revvity has a net margin of 8.26% compared to Avantor's net margin of -8.42%. Avantor's return on equity of 9.95% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avantor	-8.42%	9.95%	4.78%
Revvity	8.26%	8.00%	4.83%

95.1% of Avantor shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 0.3% of Avantor shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avantor has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Revvity has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Avantor presently has a consensus price target of $11.39, suggesting a potential upside of 42.68%. Revvity has a consensus price target of $107.73, suggesting a potential upside of 8.69%. Given Avantor's higher probable upside, equities research analysts clearly believe Avantor is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avantor	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07
Revvity	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23

Revvity has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avantor	$6.55B	0.83	-$530.20M	-$0.81	N/A
Revvity	$2.86B	3.88	$241.20M	$2.09	47.42

In the previous week, Revvity had 19 more articles in the media than Avantor. MarketBeat recorded 28 mentions for Revvity and 9 mentions for Avantor. Avantor's average media sentiment score of 1.03 beat Revvity's score of 0.32 indicating that Avantor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avantor	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	5 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Revvity beats Avantor on 11 of the 16 factors compared between the two stocks.

How does Avantor compare to Thermo Fisher Scientific?

Avantor (NYSE:AVTR) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Thermo Fisher Scientific has higher revenue and earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avantor	$6.55B	0.83	-$530.20M	-$0.81	N/A
Thermo Fisher Scientific	$44.56B	3.77	$6.70B	$18.19	24.86

In the previous week, Thermo Fisher Scientific had 32 more articles in the media than Avantor. MarketBeat recorded 41 mentions for Thermo Fisher Scientific and 9 mentions for Avantor. Thermo Fisher Scientific's average media sentiment score of 1.05 beat Avantor's score of 1.03 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avantor	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Thermo Fisher Scientific	30 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Avantor has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Thermo Fisher Scientific has a net margin of 15.15% compared to Avantor's net margin of -8.42%. Thermo Fisher Scientific's return on equity of 16.86% beat Avantor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avantor	-8.42%	9.95%	4.78%
Thermo Fisher Scientific	15.15%	16.86%	8.15%

95.1% of Avantor shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.3% of Avantor shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avantor presently has a consensus price target of $11.39, suggesting a potential upside of 42.68%. Thermo Fisher Scientific has a consensus price target of $619.65, suggesting a potential upside of 37.05%. Given Avantor's higher probable upside, equities research analysts clearly believe Avantor is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avantor	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07
Thermo Fisher Scientific	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Thermo Fisher Scientific beats Avantor on 14 of the 17 factors compared between the two stocks.

Get Avantor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTR vs. The Competition

Export

Metric	Avantor	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$5.67B	$8.21B	$6.24B	$22.90B
Dividend Yield	N/A	2.86%	2.78%	4.03%
P/E Ratio	-9.86	22.54	20.86	28.90
Price / Sales	0.83	16.46	554.55	108.04
Price / Cash	5.49	12.66	27.81	19.21
Price / Book	0.98	4.92	9.77	4.65
Net Income	-$530.20M	$183.43M	$3.54B	$1.07B
7 Day Performance	-0.75%	1.65%	-0.22%	-0.14%
1 Month Performance	1.14%	7.48%	6.28%	3.95%
1 Year Performance	-38.47%	-1.22%	39.17%	25.39%

Avantor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTR Avantor	4.4106 of 5 stars	$7.99 -3.9%	$11.39 +42.7%	-33.6%	$5.67B	$6.55B	N/A	13,500	Positive News Analyst Upgrade
TECH Bio-Techne	3.7619 of 5 stars	$54.74 -0.5%	$72.77 +32.9%	-5.1%	$8.61B	$1.22B	107.34	3,100	Positive News Earnings Report Dividend Announcement
A Agilent Technologies	4.9224 of 5 stars	$112.15 -2.1%	$163.71 +46.0%	+4.5%	$32.36B	$6.95B	24.76	18,100	Analyst Downgrade
DHR Danaher	4.7372 of 5 stars	$174.29 -0.5%	$240.70 +38.1%	-12.1%	$123.97B	$24.57B	33.71	60,000	Positive News Dividend Announcement
RVTY Revvity	2.7452 of 5 stars	$86.79 +0.1%	$109.36 +26.0%	+8.7%	$9.69B	$2.86B	41.73	11,000	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AVTR) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avantor (AVTR) Competitors